Endpoints News 18 févr. 2026 Charles River highlights increase in demand as tariff uncertainties fade
Endpoints News 18 févr. 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News 18 févr. 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 18 févr. 2026 Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Endpoints News 17 févr. 2026 FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher